Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference Live Audio Webcast Will be on December 14, 2017
PR Newswire 7-Dec-2017 1:15 PM
SAN DIEGO, Dec. 7, 2017 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference at 11:00 a.m. ET on Thursday, Dec. 14, 2017, in New York City. Timothy P. Coughlin, Vice President Finance of Neurocrine Biosciences, will present at the conference.
The live presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.
About Neurocrine Biosciences, Inc.Neurocrine Biosciencesis aSan Diegobased biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA (valbenazine) capsules inthe United Statesfor the treatment of adults with tardive dyskinesia.INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia.The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered withAbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
View original content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference-300568103.html
SOURCE Neurocrine Biosciences, Inc.